The FDA moved toward a streamlined system for drug establishment registration as it looks to simplify how factory registrations are handled for products made for the U.S. market. In a proposal described as part of broader efforts to strengthen the drug supply chain, the agency outlined changes aimed at reducing friction for distributed biopharma manufacturing while maintaining oversight. The FDA’s action follows ongoing industry discussions about how regulatory registration logistics can slow scaling and distribution, particularly as contract manufacturing networks broaden and decentralized production models grow. For regulated manufacturers and CDMOs, the proposal would be a meaningful operational shift because registration requirements are tied to compliance status, timelines for production changes, and the ability to add or modify manufacturing sites.